135 related articles for article (PubMed ID: 16469006)
1. Current role of prostate-specific antigen kinetics in managing patients with prostate cancer.
Teahan SJ; Klotz LH
BJU Int; 2006 Mar; 97(3):451-5. PubMed ID: 16469006
[No Abstract] [Full Text] [Related]
2. Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies.
Parekh DJ; Ankerst DP; Thompson IM
J Natl Cancer Inst; 2007 Apr; 99(7):496-7. PubMed ID: 17405989
[No Abstract] [Full Text] [Related]
3. Prostate-specific antigen kinetics and the diagnosis and management of prostate cancer.
Goldstraw MA; Fitzpatrick JM; Kirby RS
BJU Int; 2006 Dec; 98(6):1141-2. PubMed ID: 17125469
[No Abstract] [Full Text] [Related]
4. Prostate specific antigen kinetics in the management of prostate cancer.
Sengupta S; Amling C; D'Amico AV; Blute ML
J Urol; 2008 Mar; 179(3):821-6. PubMed ID: 18221963
[TBL] [Abstract][Full Text] [Related]
5. [Role of density of prostate-specific antigen transitory zone in early diagnosis of prostate cancer].
Topuzov ME
Vopr Onkol; 2007; 53(3):295-7. PubMed ID: 18198610
[TBL] [Abstract][Full Text] [Related]
6. Re: Editorial: the central role of prostate specific antigen in diagnosis and progression of prostate cancer.
Lawrence G
J Urol; 1996 Aug; 156(2 Pt 1):484. PubMed ID: 8683715
[No Abstract] [Full Text] [Related]
7. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
9. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
Meeks JJ; Thaxton CS; Loeb S; Roehl KA; Helfand BT; Catalona WJ
J Urol; 2008 Apr; 179(4):1340-3. PubMed ID: 18289590
[TBL] [Abstract][Full Text] [Related]
10. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
[TBL] [Abstract][Full Text] [Related]
11. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
12. Screening by lower urinary tract symptoms vs asymptomatic prostate-specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome.
Borre M
BJU Int; 2009 Jul; 104(2):205-8. PubMed ID: 19154477
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3).
Kirby RS; Fitzpatrick JM; Irani J
BJU Int; 2009 Feb; 103(4):441-5. PubMed ID: 19154510
[TBL] [Abstract][Full Text] [Related]
14. Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists.
Penson D; Moul J; Gandhi S; Newling D
Urology; 2006 Jul; 68(1):80-4. PubMed ID: 16777198
[TBL] [Abstract][Full Text] [Related]
15. Is routine digital rectal examination required for the followup of prostate cancer?
Warren KS; McFarlane JP
J Urol; 2007 Jul; 178(1):115-9. PubMed ID: 17499293
[TBL] [Abstract][Full Text] [Related]
16. Risk factors, prevention and early detection of prostate cancer.
Loeb S; Schaeffer EM
Prim Care; 2009 Sep; 36(3):603-21. PubMed ID: 19616157
[TBL] [Abstract][Full Text] [Related]
17. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy.
Donovan MJ; Hamann S; Clayton M; Khan FM; Sapir M; Bayer-Zubek V; Fernandez G; Mesa-Tejada R; Teverovskiy M; Reuter VE; Scardino PT; Cordon-Cardo C
J Clin Oncol; 2008 Aug; 26(24):3923-9. PubMed ID: 18711180
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
Lilja H; Ulmert D; Vickers AJ
Nat Rev Cancer; 2008 Apr; 8(4):268-78. PubMed ID: 18337732
[TBL] [Abstract][Full Text] [Related]
20. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
